Risk stratification of Stage B heart failure with BNP levels of 35–100 pg/mL: development of the PHASE Index from the CHART-2 Study
Open Access
- 2 September 2026
- journal article
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 6 (5)
Abstract
Aims: B-type natriuretic peptide (BNP) levels of 35–100 pg/mL, common in preclinical heart failure (HF), are associated with heterogeneous prognosis and are influenced by age and renal function. We aimed to characterize risk heterogeneity in preclinical HF patients with BNP levels of 35–100 pg/mL and to develop a practical risk stratification model. Methods and results: Data from the Chronic Heart Failure Registry and Analysis in the Tohoku District-2 (CHART-2) Study, a prospective multicentre cohort with long-term follow-up, were analysed. Among patients with Stage B HF (n = 4074; age 67.6 ± 12.0 years), the predictability of BNP for 10-year HF-related events was evaluated across strata of age and estimated glomerular filtration rate (eGFR). In patients with BNP levels of 35–100 pg/mL, a composite risk score—the Pre-Heart Failure Assessment and Screening Evaluation (PHASE) Index—was developed using classification and regression tree analysis and multivariable Cox proportional hazards modelling. BNP discrimination varied significantly by age and eGFR (P < 0.05), indicating that a single BNP threshold is insufficient for risk stratification in preclinical HF. The PHASE Index, incorporating age, BNP, eGFR, left ventricular ejection fraction, body mass index, and hypertension, stratified patients with BNP levels of 35–100 pg/mL into four categories and demonstrated superior discrimination compared with BNP alone (c-index 0.723 vs. 0.587, P < 0.05). Conclusion: Patients with preclinical HF and BNP levels of 35–100 pg/mL exhibit substantial risk heterogeneity. The PHASE Index improves identification of high-risk individuals and provides a pragmatic tool for risk stratification beyond the conventional BNP threshold.Keywords
Funding Information
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology
This publication has 25 references indexed in Scilit:
- Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure SocietyJournal of Cardiac Failure, 2023
- Prognostic Impacts of Dynamic Cardiac Structural Changes in Heart Failure Patients with Preserved Left Ventricular Ejection FractionEuropean Journal of Heart Failure, 2020
- Risk of de-novo heart failure and competing risk in asymptomatic patients with structural heart diseasesInternational Journal of Cardiology, 2020
- Conversion formula from B-type natriuretic peptide to N-terminal proBNP values in patients with cardiovascular diseasesInternational Journal of Cardiology, 2019
- Ratio of pro-B-type natriuretic peptide (BNP) to total BNP is decreased in mild, but not severe, acute decompensated heart failure patients: A novel compensatory mechanism for acute heart failureInternational Journal of Cardiology, 2018
- Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic reviewHeart Failure Reviews, 2014
- Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidenceHeart Failure Reviews, 2014
- Natriuretic Peptide–Based Screening and Collaborative Care for Heart FailureJAMA, 2013
- Risk Stratification for In-Hospital Mortality in Acutely Decompensated Heart FailureClassification and Regression Tree AnalysisJAMA, 2005
- Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational studyAmerican Heart Journal, 2004